Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven By Elevated LDL Cholesterol or By Decreased HDL Cholesterol? Response to Schulze and Hoffmann
Posted on: Sunday, 8 May 2005, 03:00 CDT
Our study (1) demonstrates that an LDL-related lipid factor in coronary patients with type 2 diabetes is 1) not elevated, 2) not associated with significant coronary stenoses, and 3) not significantly predictive for future events. Whereas the first two findings did not even show a trend for the LDL-related factor, our prospective data need to be confirmed by a longer follow-up with more end points. We have amply discussed this in our report, and Schulze and Hoffmann (2) also raise this point.
Since currently -58% of coronary patients are on statins (3) and lipid-lowering medication very frequently is required in diabetes to achieve the stringent LDL cholesterol goals that have been put forth for this "CAD risk equivalent," exclusion of diabetic patients on lipid-lowering therapy in our investigation would have excluded diabetic coronary patients receiving up-to-date medical care and thus would have rendered the study population utterly unrepresentative of today's clinical setting.
Factor analysis is the appropriate technique to extract an integral factor representing diabetic dyslipidemia from the individual lipid parameters measured. The power of this factor to predict vascular events can be subsequently evaluated in Cox regression models. This approach is novel in the study of lipid risk factors in patients with diabetes but has been previously applied to investigate the metabolic syndrome (4).
We included apolipoprotein B levels in our factorial analysis. Non-HDL cholesterol represents the total cholesterol carried by VLDL, IDL (intermediate-density lipoprotein), and LDL, of which each particle contains one molecule of apolipoprotein B. Serum levels of apolipoprotein B are thus closely related to non-HDL cholesterol.
Even though cardiovascular risk is significantly reduced in diabetic patients by statins, it remains at a very high level in these patients (5). The consistent association of the HDL-related factor with glycemia, with significant stenoses and with the future incidence of vascular events, provides compelling and conclusive evidence that the main lipid risk factor in our patients with diabetes is the triad of low HDL cholesterol, small LDL particles, and high triglycerides.
References
1. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH: Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28:101-107, 2005
2. Schulze MB, Hoffmann K: Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? (Letter). Diabetes Care 28:1264, 2005
3. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries: EUROASPIRE I and II Group: European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357:995-1001, 2001
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709- 2716, 2002
5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
HEINZ DREXEL, MD1,2
STEFAN ACZEL, MD1,2
THOMAS MARTE, MD1
WERNER BENZER, MD2
PETER LANGER, PHD1
WILLI MOLL, MD3
CHRISTOPH H. SAELY, MD1,2
From the 1 Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; the 2 Department of Medicine, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; and the 3 Institute for Clinical Chemistry, Feldkirch, Austria.
Address correspondence to Heinz Drexel, MD, Professor of Medicine, VIVIT, Carinagasse 47, A-6800 Feldkirch, Austria. E-mail: vivit@lkhf.at.
2005 by the American Diabetes Association.
Copyright American Diabetes Association May 2005
Source: Diabetes Care
Related Articles
- Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
- Otamixaban For The Treatment Of Patients With Non-ST-Elevation Acute Coronary Syndromes
- VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
- First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
- Vitreoretinal Technologies, Inc. Announces the Enrollment of First Patients for Its Phase III Clinical Trial for Vitreosolve for Diabetic Retinopathy Patients in the U.S. And India
- Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
- Presentation of In Vivo HDL Kinetic Data at the European Atherosclerosis Society 76th Congress Demonstrates Activation of Reverse Cholesterol Transport By Pre-Beta HDL in Selectively Delipidated Plasma
- Isis Cholesterol Drug Lowers LDL Levels
- Growing Diabetes Epidemic: Patient/Physician Disconnect on Disease Management
- CHARM Program Evaluates Effects of ATACAND(R) (Candesartan Cilexetil) on the Development of Diabetes in Patients With Heart Failure
 |
 |
User Comments (0)
RSS Feeds